172 related articles for article (PubMed ID: 26585370)
1. Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy.
Yuan Z; Li J; Hu R; Jiao Y; Han Y; Weng Q
Sci Rep; 2015 Nov; 5():16482. PubMed ID: 26585370
[TBL] [Abstract][Full Text] [Related]
2. Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement.
Li DJ; Xiao D
BMC Cancer; 2017 Jul; 17(1):501. PubMed ID: 28743242
[TBL] [Abstract][Full Text] [Related]
3. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic Association between
Zhang N; Ouyang Y; Chang J; Liu P; Tian X; Yu J
Biomed Res Int; 2020; 2020():3520764. PubMed ID: 33150172
[TBL] [Abstract][Full Text] [Related]
5. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis.
Cui Z; Yin Z; Li X; Wu W; Guan P; Zhou B
BMC Cancer; 2012 Feb; 12():71. PubMed ID: 22339849
[TBL] [Abstract][Full Text] [Related]
6. Role of GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln gene polymorphisms in the clinical outcome of advanced non-small cell lung cancer.
Zhao R; Chen G
Int J Clin Exp Pathol; 2015; 8(11):14909-16. PubMed ID: 26823821
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis.
Li L; Wan C; Wen FQ
Genet Mol Res; 2014 May; 13(2):3772-86. PubMed ID: 24938464
[TBL] [Abstract][Full Text] [Related]
9. Role of XRCC1 gene polymorphisms in non-small cell lung cancer cisplatin-based chemotherapy, and their effect on clinical and pathological characteristics.
Liu HF; Liu JS; Deng JH; Wu RR
Genet Mol Res; 2016 Dec; 15(4):. PubMed ID: 28081275
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.
Zhang L; Ma W; Li Y; Wu J; Shi GY
Genet Mol Res; 2014 Jan; 13(1):228-36. PubMed ID: 24446315
[TBL] [Abstract][Full Text] [Related]
11. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
[TBL] [Abstract][Full Text] [Related]
12. Association between XRCC1 Arg399Gln polymorphism and hepatitis virus-related hepatocellular carcinoma risk in Asian population.
Wu D; Jiang H; Gu Q; Zhang D; Li Z
Tumour Biol; 2013 Oct; 34(5):3265-9. PubMed ID: 23780894
[TBL] [Abstract][Full Text] [Related]
13. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.
Chen J; Zhao QW; Shi GM; Wang LR
J Zhejiang Univ Sci B; 2012 Nov; 13(11):875-83. PubMed ID: 23125080
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy: a systematic review and meta-analysis.
Xu J; Ma J; Zong HT; Wang SY; Zhou JW
Genet Mol Res; 2014 Mar; 13(1):1438-46. PubMed ID: 24634242
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis.
Wu J; Liu J; Zhou Y; Ying J; Zou H; Guo S; Wang L; Zhao N; Hu J; Lu D; Jin L; Li Q; Wang JC
Clin Cancer Res; 2012 Jul; 18(14):3972-81. PubMed ID: 22705987
[TBL] [Abstract][Full Text] [Related]
16. Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer.
Przybylowska-Sygut K; Stanczyk M; Kusinska R; Kordek R; Majsterek I
Clin Breast Cancer; 2013 Feb; 13(1):61-8. PubMed ID: 23103366
[TBL] [Abstract][Full Text] [Related]
17. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
18. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
[TBL] [Abstract][Full Text] [Related]
19. XRCC1 polymorphisms are associated with cervical cancer risk and response to chemotherapy: a systematic review and meta-analysis.
Shuai HL; Luo X; Yan RL; Li J; Chen DL
Asian Pac J Cancer Prev; 2012; 13(12):6423-7. PubMed ID: 23464469
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advanced North Indian lung cancer patients treated with platinum-based doublet chemotherapy.
Singh A; Singh N; Behera D; Sharma S
Med Oncol; 2017 Apr; 34(4):64. PubMed ID: 28332164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
